Segmentation by type classifies AR inhibitors into three chemical families: small‑molecule antagonists, peptide‑based modulators, and biologic agents such as monoclonal antibodies. Small‑molecule antagonists dominate the market, representing roughly 80 % of sales, because they offer oral bioavailability, established manufacturing processes, and a broad pipeline of next‑generation candidates designed to overcome resistance mutations. Peptide‑based modulators, accounting for about 12 % of the market, leverage higher specificity for the ligand‑binding domain and are typically administered intravenously; their niche adoption reflects limited commercial approvals but growing interest in conjugate strategies. Biologic agents, comprising the remaining 8 %, include monoclonal antibodies that block extracellular androgen binding or induce receptor degradation; although still early‑stage, they illustrate a diversification trend as developers seek mechanisms beyond competitive inhibition. The relative market shares of each type influence R&D investment patterns, pricing dynamics, and partnership activity, providing a clear market taxonomy for stakeholders evaluating technology risk and commercial upside. Regulatory pathways also differ, with small molecules following standard NDAs, while biologics require biologics licensing applications, further shaping market dynamics.
